Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, ...

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant ...

Abbott Laboratories (NYSE: ABT) is a leader in coronavirus testing. Its laboratory tests and rapid tests have brought in billions of dollars in revenue. In the fourth quarter of last year, for example ...

Abbott Laboratories reported organic sales growth of 35% in its diagnostics unit on the back of strong demand for COVID-19 testing, according to the company’s earnings report released Wednesday ...

Abbott Laboratories narrowed its full-year outlook as sales of COVID-19 tests slide. COVID-19 test sales in the second quarter dropped 46% from the year before. Second-quarter earnings and revenue ...

Abbott Laboratories first quarter profits eclipsed $2.4 billion thanks to a surge in sales of Covid-19 diagnostic tests, the company said April 20, 2022. In this photo, Abbott Chairman of the Board ...

Jan 26 (Reuters) - Abbott Laboratories (ABT.N), opens new tab on Wednesday beat quarterly profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for its diagnostics ...

Abbott (ABT) reports Q2 earnings July 15; see EPS/revenue forecasts, analyst outlook on Exact Sciences MCED test, and what to ...

LAS VEGAS, NEVADA - JANUARY 06: Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada. CES, the ...